2020 Encephalitis Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Encephalitis pipeline report presents a comprehensive overview of the research and development of Encephalitis drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Seven drugs in Pre-clinical phase, one drug in Phase 1 and one drug in Phase 2
As of February 2020, the Encephalitis pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Encephalitis treatment. Diverse types of targeted therapies are being explored through clinical trials including CD20 antigen inhibitor; NMDA receptor agonist; Immunostimulants.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Encephalitis drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Encephalitis pipeline drugs profiled in the report include- CEL-1000, Cerium dioxide, Immune modifying particle (IMP) technology for Encephalitis, ocrelizumab, miltefosine, NE3413, 13-valent pneumococcal vaccine, 23-valent pneumococcal vaccine, SAGE-718
As of February 2020, the Encephalitis pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Encephalitis treatment. Diverse types of targeted therapies are being explored through clinical trials including CD20 antigen inhibitor; NMDA receptor agonist; Immunostimulants.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Encephalitis drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Encephalitis development
- Encephalitis pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Encephalitis pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Encephalitis pipeline candidates included
- Business overview and snapshot of all companies involved in Encephalitis pipeline are included
- Latest market and pipeline developments are provided in the report
Encephalitis pipeline drugs profiled in the report include- CEL-1000, Cerium dioxide, Immune modifying particle (IMP) technology for Encephalitis, ocrelizumab, miltefosine, NE3413, 13-valent pneumococcal vaccine, 23-valent pneumococcal vaccine, SAGE-718
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Encephalitis Condition
2.3 Encephalitis Pipeline Snapshot, 2020
2.4 Companies investing in Encephalitis pipeline therapeutics
2.5 Phase wise Encephalitis Pipeline Candidates
2.6 Most Researched Mechanism of Action of Encephalitis Pipeline Products
2.7 Route of Administration of Encephalitis Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 CEL-SCI Corp Overview, Contacts and ASD Pipeline Drugs
3.2 Cerion LLC Overview, Contacts and ASD Pipeline Drugs
3.3 Cour Pharmaceutical Development Company Inc Overview, Contacts and ASD Pipeline Drugs
3.4 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Knight Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 NeurMedix Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Olymvax Biopharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Sage Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 CEL-1000 Drug Details
4.1.1 CEL-1000 Current Status
4.1.2 CEL-1000 Drug Overview
4.1.3 CEL-1000 Mechanism of Action
4.1.4 CEL-1000 Licensing/Collaboration Companies
4.1.5 CEL-1000 Clinical Trials
4.2 Cerium dioxide Drug Details
4.2.1 Cerium dioxide Current Status
4.2.2 Cerium dioxide Drug Overview
4.2.3 Cerium dioxide Mechanism of Action
4.2.4 Cerium dioxide Licensing/Collaboration Companies
4.2.5 Cerium dioxide Clinical Trials
4.3 Immune modifying particle (IMP) technology for Encephalitis Drug Details
4.3.1 Immune modifying particle (IMP) technology for Encephalitis Current Status
4.3.2 Immune modifying particle (IMP) technology for Encephalitis Drug Overview
4.3.3 Immune modifying particle (IMP) technology for Encephalitis Mechanism of Action
4.3.4 Immune modifying particle (IMP) technology for Encephalitis Licensing/Collaboration Companies
4.3.5 Immune modifying particle (IMP) technology for Encephalitis Clinical Trials
4.4 ocrelizumab Drug Details
4.4.1 ocrelizumab Current Status
4.4.2 ocrelizumab Drug Overview
4.4.3 ocrelizumab Mechanism of Action
4.4.4 ocrelizumab Licensing/Collaboration Companies
4.4.5 ocrelizumab Clinical Trials
4.5 miltefosine Drug Details
4.5.1 miltefosine Current Status
4.5.2 miltefosine Drug Overview
4.5.3 miltefosine Mechanism of Action
4.5.4 miltefosine Licensing/Collaboration Companies
4.5.5 miltefosine Clinical Trials
4.6 NE3413 Drug Details
4.6.1 NE3413 Current Status
4.6.2 NE3413 Drug Overview
4.6.3 NE3413 Mechanism of Action
4.6.4 NE3413 Licensing/Collaboration Companies
4.6.5 NE3413 Clinical Trials
4.7 13-valent pneumococcal vaccine Drug Details
4.7.1 13-valent pneumococcal vaccine Current Status
4.7.2 13-valent pneumococcal vaccine Drug Overview
4.7.3 13-valent pneumococcal vaccine Mechanism of Action
4.7.4 13-valent pneumococcal vaccine Licensing/Collaboration Companies
4.7.5 13-valent pneumococcal vaccine Clinical Trials
4.8 23-valent pneumococcal vaccine Drug Details
4.8.1 23-valent pneumococcal vaccine Current Status
4.8.2 23-valent pneumococcal vaccine Drug Overview
4.8.3 23-valent pneumococcal vaccine Mechanism of Action
4.8.4 23-valent pneumococcal vaccine Licensing/Collaboration Companies
4.8.5 23-valent pneumococcal vaccine Clinical Trials
4.9 SAGE-718 Drug Details
4.9.1 SAGE-718 Current Status
4.9.2 SAGE-718 Drug Overview
4.9.3 SAGE-718 Mechanism of Action
4.9.4 SAGE-718 Licensing/Collaboration Companies
4.9.5 SAGE-718 Clinical Trials
5. LATEST ENCEPHALITIS PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Encephalitis Condition
2.3 Encephalitis Pipeline Snapshot, 2020
2.4 Companies investing in Encephalitis pipeline therapeutics
2.5 Phase wise Encephalitis Pipeline Candidates
2.6 Most Researched Mechanism of Action of Encephalitis Pipeline Products
2.7 Route of Administration of Encephalitis Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 CEL-SCI Corp Overview, Contacts and ASD Pipeline Drugs
3.2 Cerion LLC Overview, Contacts and ASD Pipeline Drugs
3.3 Cour Pharmaceutical Development Company Inc Overview, Contacts and ASD Pipeline Drugs
3.4 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Knight Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 NeurMedix Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Olymvax Biopharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Sage Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 CEL-1000 Drug Details
4.1.1 CEL-1000 Current Status
4.1.2 CEL-1000 Drug Overview
4.1.3 CEL-1000 Mechanism of Action
4.1.4 CEL-1000 Licensing/Collaboration Companies
4.1.5 CEL-1000 Clinical Trials
4.2 Cerium dioxide Drug Details
4.2.1 Cerium dioxide Current Status
4.2.2 Cerium dioxide Drug Overview
4.2.3 Cerium dioxide Mechanism of Action
4.2.4 Cerium dioxide Licensing/Collaboration Companies
4.2.5 Cerium dioxide Clinical Trials
4.3 Immune modifying particle (IMP) technology for Encephalitis Drug Details
4.3.1 Immune modifying particle (IMP) technology for Encephalitis Current Status
4.3.2 Immune modifying particle (IMP) technology for Encephalitis Drug Overview
4.3.3 Immune modifying particle (IMP) technology for Encephalitis Mechanism of Action
4.3.4 Immune modifying particle (IMP) technology for Encephalitis Licensing/Collaboration Companies
4.3.5 Immune modifying particle (IMP) technology for Encephalitis Clinical Trials
4.4 ocrelizumab Drug Details
4.4.1 ocrelizumab Current Status
4.4.2 ocrelizumab Drug Overview
4.4.3 ocrelizumab Mechanism of Action
4.4.4 ocrelizumab Licensing/Collaboration Companies
4.4.5 ocrelizumab Clinical Trials
4.5 miltefosine Drug Details
4.5.1 miltefosine Current Status
4.5.2 miltefosine Drug Overview
4.5.3 miltefosine Mechanism of Action
4.5.4 miltefosine Licensing/Collaboration Companies
4.5.5 miltefosine Clinical Trials
4.6 NE3413 Drug Details
4.6.1 NE3413 Current Status
4.6.2 NE3413 Drug Overview
4.6.3 NE3413 Mechanism of Action
4.6.4 NE3413 Licensing/Collaboration Companies
4.6.5 NE3413 Clinical Trials
4.7 13-valent pneumococcal vaccine Drug Details
4.7.1 13-valent pneumococcal vaccine Current Status
4.7.2 13-valent pneumococcal vaccine Drug Overview
4.7.3 13-valent pneumococcal vaccine Mechanism of Action
4.7.4 13-valent pneumococcal vaccine Licensing/Collaboration Companies
4.7.5 13-valent pneumococcal vaccine Clinical Trials
4.8 23-valent pneumococcal vaccine Drug Details
4.8.1 23-valent pneumococcal vaccine Current Status
4.8.2 23-valent pneumococcal vaccine Drug Overview
4.8.3 23-valent pneumococcal vaccine Mechanism of Action
4.8.4 23-valent pneumococcal vaccine Licensing/Collaboration Companies
4.8.5 23-valent pneumococcal vaccine Clinical Trials
4.9 SAGE-718 Drug Details
4.9.1 SAGE-718 Current Status
4.9.2 SAGE-718 Drug Overview
4.9.3 SAGE-718 Mechanism of Action
4.9.4 SAGE-718 Licensing/Collaboration Companies
4.9.5 SAGE-718 Clinical Trials
5. LATEST ENCEPHALITIS PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
